Mageb6b1, a member of the MAGE family, emerges as a pivotal player in the intricate symphony of cellular regulation by orchestrating the negative modulation of transcription mediated by RNA polymerase II. Positioned within the nucleus, Mageb6b1 exhibits a predicted DNA-binding transcription factor activity, making it a key regulator of gene expression. Its primary function revolves around the suppression of transcriptional activity, positioning Mageb6b1 as a central component in the intricate regulatory network governing cellular processes. The orthologous relationship with human MAGEB6 further underscores the evolutionary conservation and potential significance of Mageb6b1 in the broader context of genetic control.
Activation of Mageb6b1 involves a sophisticated interplay of various mechanisms that finely tune its negative regulatory role in transcription. While not directly engaging with biological materials, the chemical modulators play a crucial role in shaping Mageb6b1's activity. These modulators act through diverse pathways, influencing epigenetic modifications, chromatin structure, and key signaling cascades. For instance, histone deacetylase (HDAC) inhibitors alter the acetylation state of histones, impacting the accessibility of transcriptional machinery to DNA. DNA demethylating agents contribute to the activation of Mageb6b1 by reducing DNA methylation, potentially influencing the binding of transcriptional regulators. Additionally, bromodomain and extraterminal domain (BET) inhibitors affect chromatin structure, indirectly promoting Mageb6b1 activity. The intricate modulation of these molecular events collectively shapes the regulatory landscape of Mageb6b1, enabling it to exert precise control over transcriptional processes within the cellular milieu. In summary, Mageb6b1 stands as a discerning participant in the orchestration of genetic information, primarily engaged in the negative regulation of RNA polymerase II-mediated transcription. Its activation, influenced by a myriad of chemical modulators, reflects the intricate dance of epigenetic modifications and signaling cascades that collectively contribute to its regulatory prowess. Understanding the nuanced interplay of these mechanisms sheds light on the intricate control Mageb6b1 exerts over gene expression, positioning it as a key player in the broader landscape of cellular regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Inhibits HDACs, leading to increased histone acetylation and activation of Mageb6b1. Enhances the negative regulation of transcription by RNA polymerase II. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Modulates NF-κB signaling, indirectly promoting Mageb6b1. Influences nuclear translocation, amplifying the negative regulation of transcription by RNA polymerase II. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA demethylating agent that activates Mageb6b1 by reducing DNA methylation. Enhances the negative regulation of transcription by RNA polymerase II. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET inhibitor affecting bromodomain proteins, promoting Mageb6b1 activity. Modulates chromatin structure, enhancing the negative regulation of transcription by RNA polymerase II. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor influencing histone acetylation, indirectly up-regulating Mageb6b1. Enhances the negative regulation of transcription by RNA polymerase II. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Activates SIRT1, impacting Mageb6b1 through modulation of histone deacetylation. Enhances the negative regulation of transcription by RNA polymerase II. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor, indirectly enhancing Mageb6b1 activity. Modulates TGF-β signaling, amplifying the negative regulation of transcription by RNA polymerase II. | ||||||
PFI 3 | 1819363-80-8 | sc-507340 | 10 mg | $300.00 | ||
Inhibits the histone methyltransferase SETD7, indirectly promoting Mageb6b1 activity. Modulates histone methylation, amplifying the negative regulation of transcription by RNA polymerase II. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
JMJD3 inhibitor influencing histone demethylation, indirectly up-regulating Mageb6b1. Modulates epigenetic marks, enhancing the negative regulation of transcription by RNA polymerase II. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
CBP/p300 inhibitor affecting acetylation, indirectly promoting Mageb6b1. Modulates chromatin structure, amplifying the negative regulation of transcription by RNA polymerase II. | ||||||